Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

The market for weight loss drugs is white-hot, and competition is heating up fast. This Danish company is already facing a ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

CVS drops Lilly's Zepbound for Novo's Wegovy in rebate-driven dealTelehealth partnerships expand access with cheaper ...

Eli Lilly and Co (LLY) reports a 45% revenue increase, driven by key products and strategic advancements in diabetes and ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

RO is a DTP telehealth company that provides nationwide services. The company offers multiple GLP-1 options and has hired a ...